Results 101 to 110 of about 4,821 (183)

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. [PDF]

Front Endocrinol (Lausanne)
Alhazmi A, le Roux CW.
europepmc   +1 more source

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [PDF]

Diabetes Obes Metab
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E.   +8 more
europepmc   +1 more source

Incretin polyagonists as an alternative to bariatric surgery to manage obesity. [PDF]

World J Gastrointest Pathophysiol
Manoj RJ, Fernandez CJ, Nair S, Pappachan JM.   +3 more
europepmc   +1 more source

Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. [PDF]

Curr Obes Rep
Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A.   +4 more
europepmc   +1 more source

Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management. [PDF]

Endocrinol Metab (Seoul)
Kwak KH, Jung CH.
europepmc   +1 more source

Pharmacological therapies for type 2 diabetes: future approaches. [PDF]

Diabetologia
Bailey CJ.
europepmc   +1 more source

Modifiable Factors Affecting the Postprandial Glycemic Response. [PDF]

J Diabetes Sci Technol
Wu Y, McLaughlin T, Gorgani S, Scheideman AF, Shao MM, Hislop BD, Hoang K, Perelman D, McGinity C, Rodgar M, Park H, Wang T, Mayer C, DuNova A, Ayers A, Ho C, Ræder H, Klonoff DC, Snyder MP.   +18 more
europepmc   +1 more source

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes [PDF]

, 2015
Crystal Brown, Geeta A. Maggu, Lisa M. Chastain, Valerie Vuylsteke   +3 more
core   +1 more source

Leptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity. [PDF]

J Biol Chem
Sun X, Brueck L, Yang D, Sheets PL, Zhou B, Ren H.   +5 more
europepmc   +1 more source

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. [PDF]

J Clin Invest
Cooper ME, van Raalte DH.
europepmc   +1 more source